Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trialEndocrine-Related Cancer - Tập 25 Số 3 - Trang 309-322 - 2018
Marianne Pavel, David J. Gross, Marta Benavent, Petros Perros, Rajaventhan Srirajaskanthan, Richard R.P. Warner, Matthew H. Kulke, Lowell Anthony, Pamela L. Kunz, Dieter Hörsch, Martin O. Weickert, Pablo Lapuerta, Wenjun Jiang, Kenneth Kassler-Taub, Suman Wason, Rosanna Fleming, Douglas Fleming, Rocio García‐Carbonero
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal p...... hiện toàn bộ
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumorsEndocrine-Related Cancer - Tập 22 Số 1 - Trang 1-9 - 2015
Mauro Cives, Pamela L. Kunz, Brian Morse, Domenico Coppola, Michael J. Schell, Tiffany Campos, Phuong Nguyen, Prachi Nandoskar, Vilay H. Khandelwal, Jonathan Strosberg
Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR1,2,3) and 5 (SSTR5). Results from preclinical studies indicate that pasireotide can inhibit neuroendocrine tumor (NET) growth more robustly than octreotidein vitro. This ...... hiện toàn bộ
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinomaEndocrine-Related Cancer - Tập 13 Số 4 - Trang 1213-1221 - 2006
Giovanni Capretti, Rossella Bettini, Edoardo Missiaglia, William Mantovani, Irene Dalai, P. Capelli, M Ferdeghini, P. Pederzoli, Aldo Scarpa, Massimo Falconi
About 40% of nonfunctioning pancreatic endocrine carcinomas (NF-PEC) cannot be cured by surgery due to advanced stage disease. Somatostatin analogues have been proposed as first line therapy in these cases. We performed a prospective phase IV study to assess the efficacy of octreotide in advanced NF-PEC and identify factors predictive of response to therapy. Twenty-one consecutive patients...... hiện toàn bộ
Status of aromatase inhibitors in relation to other breast cancer treatment modalities.Endocrine-Related Cancer - - Trang 277-291 - 1999
Joseph Ragaz
Aromatase is one of the key enzymes possibly linked with the perpetuation or even initiation of breast cancer. Modulation of its activity by the new generation inhibitors has resulted in increased responses and improved therapeutic ratio compared with those of parent aromatase inhibitors. More recent trials have shown promising results with regard to improved therapeutic ratio compared wit...... hiện toàn bộ
Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell linesEndocrine-Related Cancer - Tập 12 Số 1 - Trang 75-92 - 2005
Julie A. Vendrell, Ivan Bièche, Catherine Desmetz, Éric Badia, Sengül Tozlu, Catherine Nguyen, W Rozenbaum, Rosette Lidereau, Pascale A. Cohen
The aim of this study was to explore the pharmacological response to 4-hydroxy-tamoxifen (OH-Tam) and to estradiol (E2) in three cell lines: MVLN, a human breast carcinoma cell line derived from MCF-7, and two MVLN-derived OH-Tam-resistant (OTR) cell lines, called CL6.8 and CL6.32. The OH-Tam response in the OTR cells was associated with the development of both an agon...... hiện toàn bộ
The mechanisms and managements of hormone-therapy resistance in breast and prostate cancersEndocrine-Related Cancer - Tập 12 Số 3 - Trang 511-532 - 2005
K. M. Rau, Hong‐Yo Kang, T-L Cha, Sharon A. Miller, Mien‐Chie Hung
Breast and prostate cancer are the most well-characterized cancers of the type that have their development and growth controlled by the endocrine system. These cancers are the leading causes of cancer death in women and men, respectively, in the United States. Being hormone-dependent tumors, antihormone therapies usually are effective in prevention and treatment. However, the emergence of ...... hiện toàn bộ
Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma.Endocrine-Related Cancer - - Trang 601-610 - 2003
José I. Botella‐Carretero, J M Gal√°n, C Caballero, J. Sancho, Héctor F. Escobar‐Morreale
We studied the psychological performance and the quality of life in patients with differentiated thyroid carcinoma, either during treatment with chronic suppressive doses of levothyroxine, or during the withdrawal of levothyroxine needed to perform whole-body scanning with radioactive iodine, with those of appropriate healthy controls. Eighteen women with differentiated thyroid carcinoma a...... hiện toàn bộ
Cyclooxygenase-2: một mục tiêu cho phòng ngừa và điều trị ung thư vú. Dịch bởi AI Endocrine-Related Cancer - - Trang 97-114 - 2001
Louise R. Howe, Kotha Subbaramaiah, Anthony M.C. Brown, Andrew J. Dannenberg
Cyclooxygenase-2 (COX-2), một enzyme tổng hợp prostaglandin có khả năng cảm ứng, thường được biểu hiện ở một số bộ phận của thận và não. Biểu hiện COX-2 bất thường lần đầu tiên được báo cáo ở các bệnh lý ung thư đại tràng và adenom, và giờ đây đã được phát hiện ở nhiều loại ung thư ở người, bao gồm cả ung thư vú. Đặc biệt, sự gia tăng biểu hiện COX-2 trong tuyến vú chuột đủ để gây ra hình ...... hiện toàn bộ